Sree Harsha Tirumani

Suggest Changes
Learn More
BACKGROUND To determine the timing of earliest, best and plateau response to neoadjuvant imatinib in patients with GIST. MATERIALS AND METHODS In this IRB-approved retrospective study, we included(More)
Cancer immunotherapy is changing the imaging evaluation of cancer treatment response and treatment-related toxic effects. New emerging patterns of treatment response and treatment-related toxic(More)